Center-Authored Papers

Filters: Author is Carroll, Peter R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L et al..  2016.  Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 29(8):904-914. Abstract
Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM.  2013.  Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence.. The Prostate. 73(16):1786-95. Abstract
Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, Simko J, Carroll PR, Chan JM, Paris PL.  2016.  Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.. The Prostate. 76(4):339-348. Abstract
C
Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW.  2010.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.. Urology. 75(2):407-13. Abstract
Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D.  2015.  Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.. Science signaling. 8(403):ra116. Abstract
E
Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ et al..  2016.  Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.. European urology. Abstract
Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA et al..  2015.  Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.. PloS one. 10(7):e0132343. Abstract
H
McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA et al..  2016.  Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.. The American journal of surgical pathology. 40(11):1439-1456. Abstract
L
Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J et al..  2016.  Loss of expression of AZGP1 is associated with worse clinical outcomes in a multi-institutional radical prostatectomy cohort.. The Prostate. 76(15):1409-1419. Abstract
M
Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M et al..  2013.  A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.. Advances in anatomic pathology. 20(1):39-44. Abstract
Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME et al..  2016.  MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.. PloS one. 11(11):e0165236. Abstract
Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A et al..  2015.  A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.. The Prostate. Abstract
N
Kawachi MH, Bahnson RR, Barry M, Busby EJ, Carroll PR, Carter BH, Catalona WJ, Cookson MS, Epstein JI, Etzioni R et al..  2010.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(2):240-62.
Carroll PR, Parsons KJ, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB et al..  2016.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(5):509-19. Abstract
O
Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z et al..  2016.  Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort.. The Journal of urology. 195(2):313–320. Abstract
P
Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS et al..  2015.  Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.. European urology. Abstract
Carroll PR, Parsons KJ, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI et al..  2015.  Prostate Cancer Early Detection, Version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(12):1534-61. Abstract
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter BH, Etzioni R.  2012.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(19):5471-5478. Abstract
Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR et al..  2016.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.. European urology focus. 2(2):180-188. Abstract
T
Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford DE et al..  2012.  Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.. Urology. 79(3):633-7. Abstract
Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM et al..  2016.  Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.. The Journal of urology. Abstract
U
Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM et al..  2013.  Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(9):2442-2450. Abstract